petrelintide

all catalysts(0)

nothing on the calendar yet

News(5)

• Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
  As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
  fiercebiotech · 7d ago
• Roche cans one Carmot obesity asset as another shows best-in-class potential
  Acmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…
  biospace · 27d ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 28d ago
• #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
  Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if…
  endpoints · 2mo ago
• Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
  On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
  biopharma_dive · 3mo ago